Last Updated : July 27, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Tafinlar-Mekinist | dabrafenib trametinib | Advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation | Pending | |||
Truxima | Rituximab | Cancelled | ||||
Kivexa | Abacavir/lamivudine | HIV infection | List in a similar manner to other drugs in class | Complete | ||
TBC | abaloparatide | Osteoporosis, postmenopausal women | Withdrawn | |||
Orencia | Abatacept | Arthritis, rheumatoid | List with clinical criteria and/or conditions | Complete | ||
Orencia | Abatacept | Arthritis, Juvenile Idiopathic & Juvenile Rheumatoid | List with clinical criteria and/or conditions | Complete | ||
Orencia | Abatacept | Arthritis, Rheumatoid | List in a similar manner | Complete | ||
Orencia | Abatacept | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete | ||
Verzenio | abemaciclib | Adjuvant treatment of HR-positive, HER2-negative early breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Verzenio | Abemaciclib | Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Verzenio | abemaciclib | Adjuvant treatment of HR-positive, HER2-negative early breast cancer | Active | |||
Zytiga (Resubmission) | Abiraterone | Prostate Cancer Resubmission | Withdrawn | |||
Zytiga | Abiraterone | Withdrawn | ||||
Zytiga | Abiraterone acetate | Metastatic Castration Resistant Prostate Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
n/a | abiraterone acetate and prednisolone | High-risk non-metastatic prostate cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
N/A | abiraterone, prednisone, docetaxel | Metastatic castration sensitive prostate cancer (mCSPC) | Reimburse | Complete | ||
Dysport Therapeutic | abobotulinumtoxinA | Cervical dystonia | Reimburse with clinical criteria and/or conditions | Complete | ||
Dysport Therapeutic | abobotulinumtoxinA | lower limb spasticity | Reimburse with clinical criteria and/or conditions | Complete | ||
Dysport Therapeutic | abobotulinumtoxinA | Upper limb spasticity | Reimburse with clinical criteria and/or conditions | Complete | ||
Cibinqo | abrocitinib | Atopic dermatitis, moderate to severe | Reimburse with clinical criteria and/or conditions | Complete | ||
Calquence | Acalabrutinib | Chronic Lymphocytic Leukemia (CLL) | Reimburse with clinical criteria and/or conditions | Complete | ||
Calquence | Acalabrutinib | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | Reimburse with clinical criteria and/or conditions | Complete | ||
Campral | Acamprosate calcium | Alcohol Abstinence | List with clinical criteria and/or conditions | Complete | ||
Campral | Acamprosate calcium | Alcohol Abstinence | N/A | Complete | ||
Tudorza Genuair | Aclidinium bromide | Chronic Obstructive Pulmonary Disease | List with criteria/condition | Complete |